Arpankumar Patel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Arpankumar Patel has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Appala Peela
UNC Health Southeastern: Southeastern Health
1 shared publication- Appala Suman Peela
Department of Family Medicine, UNC Health Southeaster, Lumbertonn, NC 28358, USA
1 shared publication Hilloni Shah
GMERS Medical College and Hospital Sola
1 shared publication- Hilloni Shah
Internal Medicine, GMERS Medical College, Ahmedabad, India
1 shared publication Laseena Vaisyambath
Markham Stouffville Hospital
1 shared publication- Laseena Vaisyambath
Department of Medicine, Markham Stouffville Hospital, Markham, ON L3P7P3, Canada
1 shared publication
Latest Publications
- 9 March 2022
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 4 (1) , 1-6
Inflammatory Myofibroblastic Tumor in the Inguinal Canal: a Rare Case Report and a Literature Review
- 9 March 2022
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 4 (1) , 1-6
Inflammatory Myofibroblastic Tumor in the Inguinal Canal: a Rare Case Report and a Literature Review
- Open Access
- 4 January 2022
- Published by Springer Nature in Research Square
Inflammatory Myofibroblastic Tumor in the Inguinal canal: A Rare Case Report
Background Inflammatory myofibroblastic tumors, previously known as inflammatory pseudotumors, are rare soft tissue carcinomas with variable presentation and location. Due to non-specific symptoms and location, the diagnosis of this condition is often clinically challenging. Only a handful of case reports have been published in the literature describing this tumor, and there is still a lack of consensus on pathogenesis, risk factors, and treatment strategy. Most tumors have shown mutation in the anaplastic lymphoma receptor tyrosine kinase (ALK) gene. In this article, we describe a case of ALK-negative malignant inflammatory myofibroblastic tumor. Case A 46 years old male with no risk factors presented with a mass in the inguinal region. The ultrasound was suggestive of a mixed echoic mass suggestive of inguinal hernia, which led to surgical repair with resection of the tumor segment. Subsequently, histopathology and immunohistochemistry confirmed that the mass was an inflammatory myofibroblastic tumor which then recurred in a few years and failed to respond to multiple chemotherapy regimens, and over time, it progressively metastasized to the anterior abdominal wall and lungs. The patient is currently receiving palliative chemotherapy and symptomatic treatment. Conclusion This rare soft tissue tumor has not received much attention, and clinicians often miss the diagnosis. We stress that further study should be carried out on these soft tissue tumors, and adequate diagnostic and therapy recommendations should be developed.
- 4 January 2022
- Published by Springer Nature in Research Square
Open AccessInflammatory Myofibroblastic Tumor in the Inguinal canal: A Rare Case Report
Background Inflammatory myofibroblastic tumors, previously known as inflammatory pseudotumors, are rare soft tissue carcinomas with variable presentation and location. Due to non-specific symptoms and location, the diagnosis of this condition is often clinically challenging. Only a handful of case reports have been published in the literature describing this tumor, and there is still a lack of consensus on pathogenesis, risk factors, and treatment strategy. Most tumors have shown mutation in the anaplastic lymphoma receptor tyrosine kinase (ALK) gene. In this article, we describe a case of ALK-negative malignant inflammatory myofibroblastic tumor. Case A 46 years old male with no risk factors presented with a mass in the inguinal region. The ultrasound was suggestive of a mixed echoic mass suggestive of inguinal hernia, which led to surgical repair with resection of the tumor segment. Subsequently, histopathology and immunohistochemistry confirmed that the mass was an inflammatory myofibroblastic tumor which then recurred in a few years and failed to respond to multiple chemotherapy regimens, and over time, it progressively metastasized to the anterior abdominal wall and lungs. The patient is currently receiving palliative chemotherapy and symptomatic treatment. Conclusion This rare soft tissue tumor has not received much attention, and clinicians often miss the diagnosis. We stress that further study should be carried out on these soft tissue tumors, and adequate diagnostic and therapy recommendations should be developed.